kabutan

Pharma Foods International Co., Ltd.(2929) Summary

2929
TSE Prime
Pharma Foods International Co., Ltd.
619
JPY
+41
(+7.09%)
Mar 13, 3:30 pm JST
3.88
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
614.8
Mar 13, 10:42 pm JST
Summary Chart Historical News Financial Result
PER
11.9
PBR
1.84
Yield
4.04%
Margin Trading Ratio
2.27
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
568 JPY 3.56 USD
Previous Close Mar 12
578 JPY 3.63 USD
High Mar 13, 1:34 pm
627 JPY 3.93 USD
Low Mar 13, 9:00 am
568 JPY 3.56 USD
Volume
984,200
Trading Value
0.60B JPY 3.76M USD
VWAP
608.6 JPY 3.82 USD
Minimum Trading Value
61,900 JPY 388 USD
Market Cap
0.02T JPY 0.11B USD
Number of Trades
2,111
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
416
1-Year High Sep 11, 2025
4,808
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 209,800 885,300 4.22
Feb 27, 2026 167,000 878,100 5.26
Feb 20, 2026 129,400 900,500 6.96
Feb 13, 2026 129,900 852,800 6.57
Feb 6, 2026 132,100 864,700 6.55
Company Profile
Pharma Foods International Co., Ltd. primarily sells functional food ingredients such as GABA and folic acid egg supplements. The company is also involved in the development of antibody-based pharmaceuticals.
Sector
Foods
Pharma Foods International Co., Ltd. engages in the research, development, and manufacturing of functional ingredients, health foods, and pharmaceuticals. The company operates a B2B business, supplying materials to food and pharmaceutical manufacturers as well as distributors. They offer ingredients such as Pharma GABA, which provides stress relief and blood pressure improvement functions. Additionally, the company develops and sells its own brand products both domestically and internationally. In their B2C business, Pharma Foods International directly sells supplements, quasi-drugs, and cosmetics containing their proprietary functional ingredients to consumers through mail order. The Biomedical division conducts drug discovery research and development targeting intractable diseases such as autoimmune disorders and fibrosis, while also providing contracted services like proteome analysis. Furthermore, the company has expanded into venture capital and investment businesses.